The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Obinutuzumab (GA101) plus chlorambucil (Clb) or rituximab (R) plus Clb versus Clb alone in patients with chronic lymphocytic leukemia (CLL) and preexisting medical conditions (comorbidities): Final stage 1 results of the CLL11 (BO21004) phase III trial.
Valentin Goede
Consultant or Advisory Role - Roche (U)
Honoraria - Roche
Research Funding - Roche
Kirsten Fischer
Other Remuneration - Roche
Kathryn Humphrey
Employment or Leadership Position - Roche
Elina Asikanius
Employment or Leadership Position - Roche
Stock Ownership - Roche
Raymonde Busch
No relevant relationships to disclose
Anja Engelke
Other Remuneration - Roche
Clemens M. Wendtner
Consultant or Advisory Role - Roche
Honoraria - Roche
Olga Samoylova
No relevant relationships to disclose
Tatiana Chagorova
No relevant relationships to disclose
Marie-Sarah Dilhuydy
Honoraria - Roche
Javier De La Serna Torroba
Honoraria - Roche
Thomas Illmer
No relevant relationships to disclose
Stephen Opat
Consultant or Advisory Role - Roche
Carolyn Owen
No relevant relationships to disclose
Karl A Kreuzer
Consultant or Advisory Role - Roche
Honoraria - Roche
Expert Testimony - Roche
Anton W Langerak
No relevant relationships to disclose
Matthias Ritgen
Research Funding - Roche
Stephan Stilgenbauer
Consultant or Advisory Role - Mundipharma; Roche
Honoraria - Mundipharma; Roche
Research Funding - Mundipharma; Roche
Michael Wenger
Employment or Leadership Position - Roche/Genentech
Stock Ownership - Roche
Michael Hallek
Consultant or Advisory Role - Roche
Honoraria - Roche
Research Funding - Roche